0
BioLineRx Ltd. Banner Image

BioLineRx Ltd. has reached its limit for free report views

Work for BioLineRx Ltd.? Upgrade Your Profile and unlock all your annual reports.

BioLineRx Ltd.

  • Ticker BLRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioLineRx Ltd. Logo Image
  • 11-50 Employees
  • Based in Modi’in, Israel
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization. The Company's lead program, motixafortide (BL-8040), is a cancer therapy platformMore currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.
BioLineRx Ltd.

Most Recent Annual Report

BioLineRx Ltd. MOST RECENT 2019 Annual Report

Report Locked. BioLineRx Ltd. has reached its limit for free report views.

Older/Archived Annual Reports